Martin Babler
CIK: 0001435618
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 23, 2026MPLT
MapLight Therapeutics, Inc.
Award(A)Direct7.9K shares- - Jun 9, 2026PRLD
Prelude Therapeutics Inc
Award(A)DirectDirector Stock Option (Right to Buy)
38K shares- - Jan 26, 2026ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
745.9K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
56.4K shares- - Oct 30, 2025ETNB
89bio, Inc.
Disposition(D)DirectStock Option (Right to Buy)
67.7K shares- - Jul 29, 2025ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
150K shares- - Jul 29, 2025ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
662K shares- - Jun 12, 2025PRLD
Prelude Therapeutics Inc
Award(A)DirectDirector Stock Option (Right to Buy)
38K shares- - Apr 1, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect15.7K shares at avg. $6.44$101K - Feb 18, 2025ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
523K shares- - Feb 3, 2025ETNB
89bio, Inc.
Award(A)DirectStock Option (Right to Buy)
56.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 |  MPLT MapLight Therapeutics, Inc. | Award(A) | 7,864 | - | $0 | Direct |
| Jun 9, 2026 |  PRLD Prelude Therapeutics Inc | Award(A) Director Stock Option (Right to Buy) | 38,000 | - | - | Direct |
| Jan 26, 2026 |  ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 745,875 | - | - | Direct |
| Oct 30, 2025 |  ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 56,400 | - | - | Direct |
| Oct 30, 2025 | ETNB 89bio, Inc. | Disposition(D) Stock Option (Right to Buy) | 67,700 | - | - | Direct |
| Jul 29, 2025 | ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 150,000 | - | - | Direct |
| Jul 29, 2025 | ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 662,000 | - | - | Direct |
| Jun 12, 2025 | PRLD Prelude Therapeutics Inc | Award(A) Director Stock Option (Right to Buy) | 38,000 | - | - | Direct |
| Apr 1, 2025 | ALMS ALUMIS INC. | Purchase(P) | 15,650 | $6.44 | $100,733 | Indirect |
| Feb 18, 2025 | ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 523,000 | - | - | Direct |
| Feb 3, 2025 | ETNB 89bio, Inc. | Award(A) Stock Option (Right to Buy) | 56,400 | - | - | Direct |
1-11 of 11 transactions
About Babler Martin
Babler Martin (SEC CIK 0001435618) files insider reports with the SEC as Director of MapLight Therapeutics, Inc. (MPLT), Director of Prelude Therapeutics Inc (PRLD) and President, CEO and Chairman of ALUMIS INC. (ALMS). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by Babler Martin (1 Form 3, 9 Form 4), filed between Feb 5, 2025 and Jun 25, 2026. Those filings report 11 transactions, from Feb 3, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Babler Martin's filings is in WILMINGTON, DE.
Recent filings by Babler Martin
- Jun 23, 2026: Grant or award of MPLT shares (Form 4, code A).
- Jun 9, 2026: Grant or award of PRLD derivative securities (Form 4, code A).
- Jan 26, 2026: Grant or award of ALMS derivative securities (Form 4, code A).
- Oct 30, 2025: Disposition to issuer transactions of ETNB derivative securities (2 lines, Form 4, code D).
- Jul 29, 2025: Grants or awards of ALMS derivative securities (2 lines, Form 4, code A).
Other insiders filing for MapLight Therapeutics, Inc. (MPLT)
- Kreitzer Anatol, Chief Discovery Officer
- GILLIS JONATHAN, CAO and Interim CFO
- Lillie James Woodruff, Chief Scientific Officer
- Hanson Kristopher, General Counsel
- Foff Erin Pennock, Chief Medical Officer
- Kroeger Christopher A., Chief Executive Officer